levodopa has been researched along with quinoxalines in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (60.00) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gash, DM; Greenamyre, JT; Honoré, T; Klockgether, T; Kurlan, R; Turski, L; Zhang, ZM | 1 |
| Honoré, T; Jähnig, P; Jenner, P; Kunow, M; Lange, KW; Löschmann, PA; Marsden, CD; Rettig, KJ; Turski, L; Wachtel, H | 1 |
| Labruyere, J; Olney, JW; Price, MT; Stewart, GR; Wang, GJ; Zorumski, CF | 1 |
| Schmidt, WJ; Zadow, B | 1 |
| Anderson, JJ; Boldry, RC; Chase, TN; Engber, TM; Kuo, S; Papa, SM | 1 |
| Goshima, Y; Misu, Y; Miyamae, T; Okumura, F; Sato, K | 1 |
| Soares-da-Silva, P | 1 |
| Soares-da-Silva, P; Vieira-Coelho, MA | 1 |
| Marin, C; Tolosa, E | 1 |
| Bonastre, M; Chase, TN; Jimenez, A; Marin, C; Tolosa, E | 1 |
| Abreu, P; Gonzalez, MC; Sanchez, JJ | 1 |
| Campos, C; Huang, LZ; Ivy Carroll, F; Ly, J; Quik, M | 1 |
| Konitsiotis, S; Maranis, S; Stamatis, D; Tsironis, C | 1 |
| Auberson, YP; Budri, M; Calcagno, M; Dekundy, A; Mabrouk, OS; Mela, F; Morari, M; Parsons, CG; Viaro, R | 1 |
| Bariotto-Dos-Santos, K; Bortolanza, M; Del Bel, E; Dos-Santos-Pereira, M; Padovan-Neto, FE; Raisman-Vozari, R; Tumas, V | 1 |
15 other study(ies) available for levodopa and quinoxalines
| Article | Year |
|---|---|
The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys.
Topics: Animals; Dopamine; Female; Globus Pallidus; Levodopa; Macaca mulatta; MPTP Poisoning; Parkinson Disease, Secondary; Quinoxalines; Rats; Receptors, AMPA; Receptors, Neurotransmitter; Synaptic Transmission | 1991 |
Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Analysis of Variance; Animals; Callithrix; Disease Models, Animal; Drug Synergism; Ibotenic Acid; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Piperazines; Quinoxalines; Rats; Rats, Inbred Strains; Receptors, N-Methyl-D-Aspartate; Substantia Nigra | 1991 |
Excitotoxicity of L-dopa and 6-OH-dopa: implications for Parkinson's and Huntington's diseases.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Chick Embryo; Dibenzocycloheptenes; Dihydroxyphenylalanine; Dizocilpine Maleate; Hippocampus; Huntington Disease; Levodopa; Neurons; Parkinson Disease; Quinoxalines; Receptors, Neurotransmitter; Retina | 1990 |
The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Catalepsy; Dizocilpine Maleate; Drug Interactions; Ergolines; Haloperidol; Levodopa; Male; Pilot Projects; Quinoxalines; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, AMPA | 1994 |
Excitatory amino acid receptor antagonists modify regional cerebral metabolic responses to levodopa in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Autoradiography; Brain; Carbon Radioisotopes; Deoxyglucose; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Organ Specificity; Oxidopamine; Quinoxalines; Rats; Rats, Sprague-Dawley | 1994 |
L-dopa potentiates presynaptic inhibitory alpha 2-adrenoceptor- but not facilitatory angiotensin II receptor-mediated modulation of noradrenaline release from rat hypothalamic slices.
Topics: Adrenergic alpha-Agonists; Angiotensin II; Animals; Brimonidine Tartrate; Hypothalamus; In Vitro Techniques; Levodopa; Male; Norepinephrine; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha; Receptors, Angiotensin; Synapses; Yohimbine | 1993 |
Renal tubular dopamine outward transfer during Na(+)-H+ exchange activation by alpha 1- and alpha 2-adrenoceptor agonists.
Topics: Adrenergic alpha-Agonists; Amiloride; Animals; Bucladesine; Colforsin; Dopamine; Hydrogen; In Vitro Techniques; Kidney Tubules; Levodopa; Phenylephrine; Phorbol 12,13-Dibutyrate; Quinoxalines; Rats; Sodium; Sphingosine | 1993 |
Nonneuronal dopamine.
Topics: Adrenergic alpha-Agonists; Amiloride; Animals; Benserazide; Biological Transport; Brimonidine Tartrate; Catechol O-Methyltransferase; Dopamine; Kidney; Kidney Cortex; Kidney Tubules; Levodopa; Models, Biological; Monoamine Oxidase; Phenylephrine; Quinoxalines; Sodium-Hydrogen Exchangers | 1998 |
Glutamate receptor-mediated mechanisms in levodopa-induced motor fluctuations in an experimental model of parkinsonism.
Topics: Animals; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Parkinson Disease, Secondary; Piperazines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Rotation; Stereotyped Behavior; Time Factors | 1999 |
Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Dextromethorphan; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Piperazines; Quinoxalines; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Riluzole; Rotation | 2000 |
Sodium nitroprusside stimulates L-DOPA release from striatal tissue through nitric oxide and cGMP.
Topics: Animals; Corpus Striatum; Cyclic GMP; Dose-Response Relationship, Drug; Levodopa; Male; Melatonin; Nitric Oxide; Nitric Oxide Donors; Nitroprusside; Oxadiazoles; Quinoxalines; Rats; Rats, Sprague-Dawley; Salicylic Acid; Superoxide Dismutase; Uric Acid | 2002 |
Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Azetidines; Benzazepines; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Levodopa; Male; Nicotinic Agonists; Oxidopamine; Parkinson Disease; Quinoxalines; Rats; Rats, Sprague-Dawley; Varenicline | 2011 |
Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamate receptor antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopa-induced dyskinesia.
Topics: Animals; Anti-Dyskinesia Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Infusions, Intraventricular; Levodopa; Male; Oxidopamine; Phenols; Piperidines; Putamen; Quinoxalines; Rats; Rats, Wistar; Receptor, Metabotropic Glutamate 5; Receptors, AMPA; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Substantia Nigra; Subthalamic Nucleus; Thiazoles | 2012 |
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Glutamic Acid; Levodopa; Male; Microdialysis; Neostriatum; Oxidopamine; Phenols; Piperidines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Substantia Nigra | 2013 |
Repurposing an established drug: an emerging role for methylene blue in L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Drug Repositioning; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Quinoxalines; Rats, Wistar; Signal Transduction | 2019 |